Article

Are Dentists Overprescribing Antibiotics?

Author(s):

Canadian researchers found a "troubling trend" in an increase in dentists prescribing antibiotics to patients.

Canadian researchers found a "troubling trend" in an increase in dentists prescribing antibiotics to patients. The team, headed by David Patrick, MD, MHSc, and colleagues at the University of British Columbia in Vancouver, BC, Canada and colleagues said the region has been working to curb overuse of these drugs out of concern about antibiotic resistance.

From 1996 to 2013, overall antibiotic use declined from defined daily doses per 1,000 person per day (DID) from 17.4 DID to 14.1 DID. But among dental surgeon it by by 62% from .98 DID to 1.59 DID. That prescribing rate increased the most for patients age 60 and over.

The team held a webinar where dentists in Canada and the US discussed their reasons for prescribing.

Those included "unnecessary prescription for periapical abscess and irreversible pulpitis; increase in use of dental implants; slow adoption of newer guidelines regarding treatment of patients with valvular heart disease and who have had joint replacement surgery Also, they found a reduction in the "surgical skill set of the average dentist" who is now more likely to get income from cosmetic procedures.

They also suggested that patients without insurance or enough insurance are treating dental problems with antibiotics because they cannot afford the oral surgery they need.

"The above themes should be further validated," the team wrote in an abstract presented at IDWeek 2015 in San Diego, CA.

Related Videos
New ‘Level Up’ Data on Upadacitinib (Rinvoq) for Atopic Dermatitis, with Christopher Bunick, MD, PhD
Julie Refardt, MD, PhD: Current Hyponatremia Clinical Interventions Sufficient
Richard Pratley, MD | Credit: Advent Health Diabetes Institute
Christopher Bunick, MD, PhD: Facts About Systemic Therapies’ Safety, Mechanism of Action
Carla Nester, MD | Credit: HCPLive
Shawn Kwatra, MD: Making the Connection Between Prurigo Nodularis, Atopic Dermatitis, and Itch
Will Herrington, MBBS, MD, MA: Empagliflozin Follow-up Data Informs Clinical Care for CKD
Jennifer Lai Yee, MD, PhD, MPH: Honing in on Sparsentan’s Benefit in Genetic FSGS
Highlighting Recent Therapies for Dermatologists, with James Del Rosso, DO
Ladan Zand, MD: Obinutuzumab Promising Option for Refractory, Primary FSGS
© 2024 MJH Life Sciences

All rights reserved.